Frontage Holdings Corporation

Frontage Holdings Corporation is a contract research organization that provides comprehensive drug discovery, drug development, pharmaceutical product development, and laboratory testing services. Its drug discovery services include medicinal chemistry, pharmacology, efficacy studies, ADME screening, and DMPK. The company also offers safety and toxicology testing, early phase clinical services, and bioequivalence services with regulatory support. In pharmaceutical product development, it handles API synthesis, process and formulation development, and clinical trial material manufacturing. Laboratory testing covers bioanalysis, biomarkers, genomics, CMC analytical testing, and central lab services. Frontage serves pharmaceutical, biotechnology, and agrochemical companies across the United States, Canada, China, Europe, India, Japan, South Korea, and Australia.

Frontage Holdings Corporation is traded on the OTC Markets under the ticker symbol FGHQF, specifically on the OTCPK (OTC Pink) exchange. The company's financial reporting and stock trading are conducted in US Dollars (USD). As an OTC-listed stock, it is not listed on major exchanges like the NYSE or Nasdaq, but it provides investors with access to the company's shares through the over-the-counter market. The choice of USD reflects its headquarters in the United States and its primary operations in the US and other global markets.

Frontage Holdings Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on providing services that support the development of new drugs and therapies, rather than manufacturing its own proprietary drugs. Its services are essential for pharmaceutical and biotech firms that need specialized expertise in drug discovery, preclinical testing, clinical trials, and laboratory analysis. The company's role as a contract research organization places it at the intersection of healthcare and scientific innovation, helping clients bring new treatments to market more efficiently.

Frontage Holdings Corporation is headquartered in Exton, Pennsylvania, United States. Founded in 2001, the company has grown to serve a global client base, operating in the United States, Canada, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. This extensive geographic reach allows Frontage to support pharmaceutical, biotechnology, and agrochemical companies worldwide with their drug development needs. The company's presence in key markets like China and Europe is particularly notable, as these regions are major hubs for pharmaceutical research and manufacturing. Its international operations enable it to offer localized support while maintaining global standards of quality and compliance.

Frontage Holdings Corporation generates revenue by providing fee-for-service contracts to pharmaceutical, biotechnology, and agrochemical companies. Its business model is based on offering a comprehensive suite of services across the drug development lifecycle. Revenue comes from drug discovery services such as medicinal chemistry and ADME screening, preclinical safety and toxicology studies, early phase clinical services, and bioequivalence testing. Additionally, the company earns from pharmaceutical product development, including API synthesis and formulation development, as well as laboratory testing services like bioanalysis, genomics, and CMC analytical testing. By serving clients across multiple geographies—including the US, China, Europe, and Asia—Frontage diversifies its revenue streams and mitigates regional risks. As a subsidiary of Hongkong Tigermed Consulting Co., Ltd., it also benefits from the backing of a larger parent company in the clinical research space.